Author:
Martin Karlyn A.,Lancki Nicola,Kreuziger Lisa Baumann,Li Celina,Eyster M. Elaine,Sanfilippo Kristen,Woller Scott C.,Rosovsky Rachel P.
Funder
Janssen Scientific Affairs
National Institutes of Health
NHLBI
National Center for Advancing Translational Sciences
Reference11 articles.
1. Oral apixaban for the treatment of acute venous thromboembolism;Agnelli;N. Engl. J. Med.,2013
2. Oral rivaroxaban for symptomatic venous thromboembolism;Investigators;N. Engl. J. Med.,2010
3. Dabigatran versus warfarin in the treatment of acute venous thromboembolism;Schulman;N. Engl. J. Med.,2009
4. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects;Kubitza;J. Clin. Pharmacol.,2007
5. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects;Upreti;Br. J. Clin. Pharmacol.,2013